|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||113.00 - 114.94|
|52 Week Range||81.12 - 121.45|
|PE Ratio (TTM)||34.61|
|Earnings Date||Oct 24, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||130.80|
The CNBC IQ100 index beating the broader market over one year up 26%. Today's leaders include UnitedHealth, Johnson & Johnson, Nike and Edwards Lifesciences.
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Edwards Lifesciences Corp. a score of 75. Our analysis is based on comparing Edwards Lifesciences Corp. with the following peers – Boston Scientific Corporation, C. R. Bard, Inc., Merit Medical Systems, Inc., LeMaitre Vascular, Inc., Dextera Surgical, Inc., ICU Medical, Inc., Medtronic plc and CryoLife, Inc. (BSX-US, ... Read more (Read more...)
Political turmoil and the health policy related battle apart, majority of the MedTech stocks' bottom line is likely to be hurt in the third quarter on escalating costs induced by consecutive hurricanes and Mexico earthquakes.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Edwards Lifesciences Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
Edwards Lifesciences (EW) will likely ride high in Q3 earnings banking on continued growth in its highly advanced Transcatheter Heart Valve Therapy space.
As of October 13, 2017, according to a Reuters survey consisting of 22 brokerage firms, 77.3% of the firms rated Edwards Lifesciences a "buy.”
According to Wall Street analysts’ estimates for 3Q17, Edwards Lifesciences is expected to have revenues of $8.3 billion, a YoY (year-over-year) sales growth of 12.5%.
Edwards Lifesciences (EW) has scheduled its 3Q17 earnings release for October 24, 2017. This leading player in the artificial heart valves market has been gaining momentum and trading near its 52-week ...
IRVINE, Calif. , Oct. 11, 2017 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, plans ...
This could indicate that investors who seek to profit from falling equity prices are not currently targeting EW. Over the last one-month, outflows of investor capital in ETFs holding EW totaled $5.84 billion.
Edwards Lifesciences (EW) rides high on product launches as well as strength in the global Transcatheter Aortic Valve Replacement market.
Medtronic (MDT) to initiate FORWARD PRO Clinical Study for evaluating the safety standards of self-expanding TAVI system over longer-term.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting EW. Over the last one-month, outflows of investor capital in ETFs holding EW totaled $3.69 billion.
With World Heart Day coming up, here is a look at some well-positioned stocks including BioTelemetry (BEAT) in this segment of the market.
Management at Allscripts Healthcare (MDRX) is focused on various restructuring initiatives, research and development plans and launch of exclusive products.
Edwards Lifesciences, Bed Bath & Beyond, Annaly Capital Management, AGNC Investment and ARMOUR Residential REIT highlighted as Zacks Bull and Bear of the Day
The market is upbeat about Omnicell's (OMCL) recently-launched XT Series Automated Supply Dispensing Cabinet. The company is also expanding its footprint globally.